X4 PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
X4 PHARMACEUTICALS, INC (XFOR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2025-03-26
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-12-31 was -$12.00K.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-06-30 was $0.00.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-03-31 was $13.00K, a 0.00% change year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.00K, a 0.00% change from fiscal 2022.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.00K, a 92.31% decline from fiscal 2021.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $13.00K, a 69.05% decline from fiscal 2020.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $42.00K, a 88.43% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-12-31 | $1.00K 10-K · filed 2025-03-26 | |||||
| 2022-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$12.00K derived: sum of 2 quarters · filed 2024-03-21 | -$12.00K derived: sum of 3 quarters · filed 2024-03-21 | $1.00K 10-K · filed 2024-03-21 | $0.00 10-K · filed 2023-03-21 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $13.00K 10-Q · filed 2022-11-03 | $13.00K derived: sum of 4 quarters · filed 2024-03-21 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $13.00K 10-Q · filed 2022-08-04 | $13.00K derived: sum of 3 quarters · filed 2024-03-21 | $13.00K derived: sum of 4 quarters · filed 2024-03-21 | ||
| 2022-03-31 | $13.00K 10-Q · filed 2022-05-12 | $13.00K derived: sum of 2 quarters · filed 2024-03-21 | $13.00K derived: sum of 3 quarters · filed 2024-03-21 | $13.00K derived: sum of 4 quarters · filed 2024-03-21 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $0.00 derived: sum of 3 quarters · filed 2024-03-21 | $13.00K 10-K · filed 2024-03-21 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $13.00K 10-Q · filed 2021-11-04 | $12.00K derived: sum of 4 quarters · filed 2023-03-21 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $13.00K 10-Q · filed 2021-08-03 | $12.00K derived: sum of 3 quarters · filed 2023-03-21 | $19.00K derived: sum of 4 quarters · filed 2023-03-21 | ||
| 2021-03-31 | $13.00K 10-Q · filed 2021-05-06 | $12.00K derived: sum of 2 quarters · filed 2023-03-21 | $19.00K derived: sum of 3 quarters · filed 2023-03-21 | $20.00K derived: sum of 4 quarters · filed 2023-03-21 | ||
| 2020-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $6.00K derived: sum of 2 quarters · filed 2023-03-21 | $7.00K derived: sum of 3 quarters · filed 2023-03-21 | $42.00K 10-K · filed 2023-03-21 | ||
| 2020-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $8.00K derived: sum of 2 quarters · filed 2021-11-04 | $43.00K 10-Q · filed 2021-11-04 | $222.00K derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $36.00K 10-Q · filed 2021-08-03 | $215.00K derived: sum of 3 quarters · filed 2021-08-03 | $269.00K derived: sum of 4 quarters · filed 2021-08-03 | ||
| 2020-03-31 | $35.00K 10-Q · filed 2021-05-06 | $214.00K derived: sum of 2 quarters · filed 2021-05-06 | $268.00K derived: sum of 3 quarters · filed 2021-05-06 | $275.00K derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $233.00K derived: sum of 2 quarters · filed 2021-03-19 | $240.00K derived: sum of 3 quarters · filed 2021-03-19 | $363.00K 10-K · filed 2021-03-19 | ||
| 2019-09-30 | $54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $61.00K derived: sum of 2 quarters · filed 2020-11-05 | $184.00K 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $130.00K 10-Q · filed 2020-08-04 | ||||
| 2019-03-31 | $123.00K 10-Q · filed 2020-05-07 | $0.00 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |